Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CRANBURY, N.J., Sept. 01, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Robert W. Baird & Co. 2016 Healthcare Conference in New York, NY on Wednesday, September 7 at 3:10pm ET.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sean Conley [email protected] (646) 381-9096
